A phase II/III trial of Arimoclomol in Amyotrophic Lateral Sclerosis (ALS)

Trial Profile

A phase II/III trial of Arimoclomol in Amyotrophic Lateral Sclerosis (ALS)

Planning
Phase of Trial: Phase II/III

Latest Information Update: 25 Oct 2017

At a glance

  • Drugs Arimoclomol (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Oct 2017 New trial record
    • 24 Oct 2017 The company is planning to start this trial in H2 2018 and complete this trial by the end of 2020, as reported in an Orphazyme media release. This study, if positive, will form the basis for a single study filing for Amyotrophic Lateral Sclerosis.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top